Controversial NIH Director Also Takes Helm at CDC Amid RFK Jr.
Jay Bhattacharya, the controversial NIH Director, has been appointed acting CDC Director, marking an unusual dual role amidst Health Secretary Robert F. Kennedy Jr.'s leadership shake-up. Critics express alarm over Bhattacharya's perceived lack of leadership and history of endorsing anti-vaccine policies, fearing further destabilization of public health agencies and a rubber-stamping of unscientific agendas.

Controversial NIH Director Also Takes Helm at CDC Amid RFK Jr. Shake-Up
Key takeaways
- Jay Bhattacharya, the current Director of the National Institutes of Health (NIH), has been appointed acting Director of the Centers for Disease Control and Prevention (CDC).
- This unusual dual role occurs amidst significant leadership changes within the Department of Health and Human Services (HHS) under anti-vaccine Secretary Robert F. Kennedy Jr.
- Bhattacharya's leadership at NIH has been criticized for defunding research, numerous vacancies, and a perceived hands-off management style.
- Public health experts express concern that he will continue to rubber-stamp Kennedy's anti-vaccine agenda, as he previously approved drastic cuts to childhood vaccine recommendations.
- His tenure as acting CDC director is temporary, legally limited to 210 days, with a deadline for a permanent nomination approaching on March 25.
What happened
Jay Bhattacharya, currently serving as the Director of the National Institutes of Health (NIH), has additionally assumed the role of acting Director for the Centers for Disease Control and Prevention (CDC). This is an uncommon arrangement that has immediately drawn sharp criticism from scientific researchers and public health experts. The appointment is part of a broader leadership restructuring within the Department of Health and Human Services (HHS), spearheaded by anti-vaccine Health Secretary Robert F. Kennedy Jr. Bhattacharya is the third leader for the CDC under Secretary Kennedy's administration, highlighting a period of significant turnover for the public health agency.
Why it matters
This dual appointment is highly significant due to the ongoing turmoil within US public health agencies and Bhattacharya's controversial record at the NIH. Critics argue that his perceived lack of hands-on leadership at NIH, which has seen hundreds of millions of dollars in research grants frozen or terminated and an unprecedented number of vacancies, makes him ill-suited to oversee two vital institutions simultaneously. The appointment raises concerns about the stability and scientific independence of both the NIH and CDC. Experts fear that Bhattacharya will further facilitate Secretary Kennedy's anti-vaccine agenda, potentially undermining evidence-based public health practices and contributing to the resurgence of preventable diseases, such as measles.
Key details / context
The CDC has experienced considerable instability under Secretary Kennedy's leadership. Susan Monarez, a microbiologist and the first Senate-confirmed CDC director under Kennedy, was ousted within a month for allegedly refusing to endorse changes to vaccine recommendations proposed by Kennedy's anti-vaccine advisors. Her successor, Jim O'Neill, a Silicon Valley investor and ally of Peter Thiel, then served as acting director and approved a dramatic overhaul of the CDC's childhood vaccine recommendations. O'Neill is reportedly now slated for nomination to lead the National Science Foundation.
While Bhattacharya, a health economist with a medical degree, possesses more relevant qualifications than O'Neill, his leadership at NIH has been contentious. A recent Senate report revealed that under his directorship, the NIH halted or froze $561 million in grants for research into the four leading causes of death in America. At least 304 clinical trials were defunded. Additionally, 16 of the NIH's 27 institutes and centers currently lack directors, marking an unprecedented number of vacancies. Bhattacharya is known for delegating most of his responsibilities to other officials and for frequent public interviews, earning him the moniker
Related articles
Exit 8 Review: A Masterful Cinematic Nightmare
Exit 8 offers a chilling, psychological horror experience, transforming a minimalist video game into a profound cinematic nightmare. Director Genki Kawamura's innovative practical filmmaking and deep thematic exploration make it a must-see for fans of unconventional horror.
Tech Moves: Microsoft Leader Jumps to Anthropic, New CEO at Tagboard
Microsoft veteran Eric Boyd has joined AI leader Anthropic to head its infrastructure team, marking a major personnel shift in the competitive AI sector. Concurrently, Tagboard, a Redmond-based live broadcast production company, announced Marty Roberts as its new CEO, succeeding Nathan Peterson. Expedia Group also promoted Ryan Desjardins to Vice President of Technology, bolstering its efforts in AI integration.
How to Buy the Right HDMI to USB-C Cable - Avoid Costly Mistakes
Learn to connect an HDMI source to a USB-C monitor by understanding unidirectional cables, active conversion, and power requirements, avoiding costly mistakes in three simple steps.
Offline-First Social Systems: The Rise of Phone-Free Venues
Mobile technology, while streamlining communication and access, has also ushered in an era of constant digital distraction. For developers familiar with context switching and notification fatigue, the impact on
Helpless AI Disruptors of the Future: High Stakes, High Risks
This review analyzes the current trend of young, college-dropout AI entrepreneurs receiving unprecedented VC support, including housing, personal chefs, and daily task management. While designed for hyper-focus, it raises concerns about sustainability, founder well-being, and parallels to past tech booms, warranting a cautious outlook.
Embattled startup Delve has ‘parted ways’ with Y Combinator: Startups
Compliance startup Delve has been removed from Y Combinator's portfolio amidst accusations of fake compliance, misleading clients, and data issues. This follows Insight Partners' earlier distancing. Delve's leadership attributes the claims to a malicious attack and has apologized, outlining steps to restore customer trust.





